The Rift Valley Fever drugs in development market research report provides comprehensive information on the therapeutics under development for Rift Valley Fever, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Rift Valley Fever. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Rift Valley Fever and features dormant and discontinued products.
GlobalData tracks six drugs in development for Rift Valley Fever by six companies/universities/institutes. The top development phase for Rift Valley Fever is preclinical with three drugs in that stage. The Rift Valley Fever pipeline has four drugs in development by companies and two by universities/ institutes. Some of the companies in the Rift Valley Fever pipeline products market are: Theravectys, Moderna and Vanderbilt University.
The key mechanisms of action in the Rift Valley Fever pipeline product include The Rift Valley Fever pipeline products include two routes of administration with the top ROA being Intramuscular and five key molecule types in the Rift Valley Fever pipeline products market including Recombinant Vector Vaccine, and mRNA Vaccine.
Rift Valley Fever overview
Rift Valley fever (RVF) is a zoonotic viral disease that primarily affects animals but can also affect humans. Contact with blood, body fluids, or tissues of the infected animals can cause RVF. Currently, no human-to-human transmission of RVF virus has been documented. RVF virus has an incubation period of 2-6 days after exposure. Symptoms include fever, weakness, back pain, and dizziness. If early symptoms do not appear, then RVF virus can cause 3 distinct syndromes: ocular disease, meningoencephalitis, or hemorrhagic fever. RVF virus infections can only be diagnosed with RT-PCR, ELISA, and virus isolation cell culture. There is no FDA approved drug to treat RVF as most of the cases are mild and self-limiting. It can be prevented by a sustained animal vaccination program.
For a complete picture of Rift Valley Fever’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
